Comparison of123I-IBZM spect and11C-raclopride PET findings in patients with parkinsonism

J. Schwarz, A. Antonini, K. Tatsch, C. M. Kirsch, W. H. Oertel, K. L. Leenders

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

We compared the results of123I-iodobenzamide (123I-IBZM) single photon emission computed tomography (SPECT) and11C-raclopride positron emission tomography (PET) in 22 patients with parkinsonism. Nineteen patients were clinically diagnosed as having Parkinson's disease, two patients presented with atypical parkinsonism (i.e. clinical signs of Parkinson's disease and a subsequent poor response to dopamimetic drugs) and one patient was diagnosed as having Wilson's disease. All patients were drug naive. The SPECT data were semiquantitatively evaluated by calculating the ratios of striatal (basal ganglia, BG) IBZM binding to IBZM binding in various reference areas, i.e. the frontal cortex (BG/FC), the occipital cortex (BG/OC) and the cerebellum (BG/CE). In PET studies similar regions of interest were derived and ratios of striatal to cerebellar raclopride activity were determined.I23I-IBZM SPECT results significantly correlated to specific11C-raclopride binding. This correlation was not significantly different when the frontal cortex (P=0.05, r=0A2), occipital cortex (P11C-raclopride binding were considered, no significant correlation was obtained. Qualitative changes of dopamine D2 receptor binding, such as asymmetry, were equally recognized. This intraindividual comparison in patients with parkinsonism proves the previous assumption that binding of ligands to dopamine D2 receptors assessed by nC-raclopride PET is reflected by123I-IBZM SPECT. However, an increase of dopamine D2 receptor binding can only be discovered by PET.

Original languageEnglish
Pages (from-to)806-813
Number of pages8
JournalNuclear Medicine Communications
Volume15
Issue number10
Publication statusPublished - 1994

Fingerprint

Raclopride
Parkinsonian Disorders
Positron-Emission Tomography
Single-Photon Emission-Computed Tomography
Dopamine D2 Receptors
Corpus Striatum
Occipital Lobe
Frontal Lobe
Basal Ganglia
Parkinson Disease
Hepatolenticular Degeneration
Pharmaceutical Preparations
Cerebellum
3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide
Ligands

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Schwarz, J., Antonini, A., Tatsch, K., Kirsch, C. M., Oertel, W. H., & Leenders, K. L. (1994). Comparison of123I-IBZM spect and11C-raclopride PET findings in patients with parkinsonism. Nuclear Medicine Communications, 15(10), 806-813.

Comparison of123I-IBZM spect and11C-raclopride PET findings in patients with parkinsonism. / Schwarz, J.; Antonini, A.; Tatsch, K.; Kirsch, C. M.; Oertel, W. H.; Leenders, K. L.

In: Nuclear Medicine Communications, Vol. 15, No. 10, 1994, p. 806-813.

Research output: Contribution to journalArticle

Schwarz, J, Antonini, A, Tatsch, K, Kirsch, CM, Oertel, WH & Leenders, KL 1994, 'Comparison of123I-IBZM spect and11C-raclopride PET findings in patients with parkinsonism', Nuclear Medicine Communications, vol. 15, no. 10, pp. 806-813.
Schwarz J, Antonini A, Tatsch K, Kirsch CM, Oertel WH, Leenders KL. Comparison of123I-IBZM spect and11C-raclopride PET findings in patients with parkinsonism. Nuclear Medicine Communications. 1994;15(10):806-813.
Schwarz, J. ; Antonini, A. ; Tatsch, K. ; Kirsch, C. M. ; Oertel, W. H. ; Leenders, K. L. / Comparison of123I-IBZM spect and11C-raclopride PET findings in patients with parkinsonism. In: Nuclear Medicine Communications. 1994 ; Vol. 15, No. 10. pp. 806-813.
@article{30242da0fb0b4c9dbd5e8c1a779b07b4,
title = "Comparison of123I-IBZM spect and11C-raclopride PET findings in patients with parkinsonism",
abstract = "We compared the results of123I-iodobenzamide (123I-IBZM) single photon emission computed tomography (SPECT) and11C-raclopride positron emission tomography (PET) in 22 patients with parkinsonism. Nineteen patients were clinically diagnosed as having Parkinson's disease, two patients presented with atypical parkinsonism (i.e. clinical signs of Parkinson's disease and a subsequent poor response to dopamimetic drugs) and one patient was diagnosed as having Wilson's disease. All patients were drug naive. The SPECT data were semiquantitatively evaluated by calculating the ratios of striatal (basal ganglia, BG) IBZM binding to IBZM binding in various reference areas, i.e. the frontal cortex (BG/FC), the occipital cortex (BG/OC) and the cerebellum (BG/CE). In PET studies similar regions of interest were derived and ratios of striatal to cerebellar raclopride activity were determined.I23I-IBZM SPECT results significantly correlated to specific11C-raclopride binding. This correlation was not significantly different when the frontal cortex (P=0.05, r=0A2), occipital cortex (P11C-raclopride binding were considered, no significant correlation was obtained. Qualitative changes of dopamine D2 receptor binding, such as asymmetry, were equally recognized. This intraindividual comparison in patients with parkinsonism proves the previous assumption that binding of ligands to dopamine D2 receptors assessed by nC-raclopride PET is reflected by123I-IBZM SPECT. However, an increase of dopamine D2 receptor binding can only be discovered by PET.",
author = "J. Schwarz and A. Antonini and K. Tatsch and Kirsch, {C. M.} and Oertel, {W. H.} and Leenders, {K. L.}",
year = "1994",
language = "English",
volume = "15",
pages = "806--813",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Comparison of123I-IBZM spect and11C-raclopride PET findings in patients with parkinsonism

AU - Schwarz, J.

AU - Antonini, A.

AU - Tatsch, K.

AU - Kirsch, C. M.

AU - Oertel, W. H.

AU - Leenders, K. L.

PY - 1994

Y1 - 1994

N2 - We compared the results of123I-iodobenzamide (123I-IBZM) single photon emission computed tomography (SPECT) and11C-raclopride positron emission tomography (PET) in 22 patients with parkinsonism. Nineteen patients were clinically diagnosed as having Parkinson's disease, two patients presented with atypical parkinsonism (i.e. clinical signs of Parkinson's disease and a subsequent poor response to dopamimetic drugs) and one patient was diagnosed as having Wilson's disease. All patients were drug naive. The SPECT data were semiquantitatively evaluated by calculating the ratios of striatal (basal ganglia, BG) IBZM binding to IBZM binding in various reference areas, i.e. the frontal cortex (BG/FC), the occipital cortex (BG/OC) and the cerebellum (BG/CE). In PET studies similar regions of interest were derived and ratios of striatal to cerebellar raclopride activity were determined.I23I-IBZM SPECT results significantly correlated to specific11C-raclopride binding. This correlation was not significantly different when the frontal cortex (P=0.05, r=0A2), occipital cortex (P11C-raclopride binding were considered, no significant correlation was obtained. Qualitative changes of dopamine D2 receptor binding, such as asymmetry, were equally recognized. This intraindividual comparison in patients with parkinsonism proves the previous assumption that binding of ligands to dopamine D2 receptors assessed by nC-raclopride PET is reflected by123I-IBZM SPECT. However, an increase of dopamine D2 receptor binding can only be discovered by PET.

AB - We compared the results of123I-iodobenzamide (123I-IBZM) single photon emission computed tomography (SPECT) and11C-raclopride positron emission tomography (PET) in 22 patients with parkinsonism. Nineteen patients were clinically diagnosed as having Parkinson's disease, two patients presented with atypical parkinsonism (i.e. clinical signs of Parkinson's disease and a subsequent poor response to dopamimetic drugs) and one patient was diagnosed as having Wilson's disease. All patients were drug naive. The SPECT data were semiquantitatively evaluated by calculating the ratios of striatal (basal ganglia, BG) IBZM binding to IBZM binding in various reference areas, i.e. the frontal cortex (BG/FC), the occipital cortex (BG/OC) and the cerebellum (BG/CE). In PET studies similar regions of interest were derived and ratios of striatal to cerebellar raclopride activity were determined.I23I-IBZM SPECT results significantly correlated to specific11C-raclopride binding. This correlation was not significantly different when the frontal cortex (P=0.05, r=0A2), occipital cortex (P11C-raclopride binding were considered, no significant correlation was obtained. Qualitative changes of dopamine D2 receptor binding, such as asymmetry, were equally recognized. This intraindividual comparison in patients with parkinsonism proves the previous assumption that binding of ligands to dopamine D2 receptors assessed by nC-raclopride PET is reflected by123I-IBZM SPECT. However, an increase of dopamine D2 receptor binding can only be discovered by PET.

UR - http://www.scopus.com/inward/record.url?scp=0028172225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028172225&partnerID=8YFLogxK

M3 - Article

C2 - 7838444

AN - SCOPUS:0028172225

VL - 15

SP - 806

EP - 813

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 10

ER -